ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2559

Increasing Clinical Trial Awareness in Sample of Underrepresented Systemic Lupus Erythematosus Patients
Abstract Number: 2560

Quality and Accuracy of TikTok Videos on Axial Spondyloarthritis: A Modified DISCERN Analysis
Abstract Number: 2561

Patient-Centricity: The Keystone to Recruitment and Retention of Research Participants for the Lupus Landmark Study and the Success of the Lupus Nexus
Abstract Number: 2562

Enhancing Hand Osteoarthritis Classification with Generative AI: A CycleGAN and EfficientNetB7 Approach
Abstract Number: 2563

Factors Associated With Medication Use in the Preconception and Perinatal Period Among Women With Autoimmune Disorders: A Systematic Review
Abstract Number: 2564

An illustration-based patient-reported outcome measure reveals concealed symptoms in patients with rheumatoid arthritis and the factor contributing to the discrepancy between patient and evaluator global assessments
Abstract Number: 2565

Assessing Participation in the Lupus Sister Circle Support Group
Abstract Number: 2566

Using Abdominal CT-Derived Bone Mineral Density and Psoas Volume for Opportunistic Osteoporosis Screening and Fracture Risk Assessment
Abstract Number: 2567

Temporal Trends in Cardiometabolic Multimorbidity Risk in Rheumatoid Arthritis: A National, Matched Cohort Study
Abstract Number: 2568

Cardiovascular Risk Prediction in Systemic Lupus Erythematosus: Comparing the PREVENT and SLECRISK Models
Abstract Number: 2569

Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Abstract Number: 2570

Accelerometer-derived ‘weekend warrior’ physical activity, genetic susceptibility, and incident rheumatoid arthritis: a prospective cohort study
Abstract Number: 2571

Rare Clinically Significant Methotrexate Toxicity Despite Frequent Laboratory Abnormalities: A Population-Based Study of Methotrexate Monitoring
Abstract Number: 2572

Multi-Modal Machine Learning Prediction and Phenotyping of Systemic Lupus Erythematosus Using Longitudinal EHR and Genomic Data from the All of Us Program
Abstract Number: 2573

Impaired Humoral Response to Recombinant Herpes Zoster Vaccine in Rituximab Treated Autoimmune Rheumatic Diseases Patients: A Prospective Controlled Phase 4 Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].